PMID- 34967946
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220513
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 62
IP  - 6
DP  - 2022 Jun
TI  - Efficacy and Safety of Adjunctive Serotonin-Dopamine Activity Modulators in Major 
      Depression: A Meta-Analysis of Randomized Controlled Trials.
PG  - 721-732
LID - 10.1002/jcph.2022 [doi]
AB  - Serotonin-dopamine activity modulators (SDAMs) have been approved as an 
      adjunctive treatment to antidepressants in patients with inadequate response. 
      These drugs have been proposed to have a beneficial effect on cognition, 
      sleep-related problems, and other affective symptoms in patients with depression. 
      Previous studies have shown inconsistent evidence and have not reported a pooled 
      effect of the 2 drugs of this class: aripiprazole and brexpiprazole. This 
      meta-analysis evaluated the effect of augmentation with SDAM drugs in patients 
      with major depression. The meta-analysis protocol was made as per Preferred 
      Reporting Items for Systematic Reviews and Meta-Analysis Protocol guidelines and 
      registered in the International Prospective Register of Ongoing Systematic 
      Reviews. The PubMed/MEDLINE, Cochrane Clinical Trial registry, and EudraCT 
      databases were searched with prespecified search terms. A random-effects 
      meta-analysis was performed using the meta package in R software. Fifteen studies 
      were included in this meta-analysis. The random-effects model analysis observed a 
      pooled effect of 1.55 (95%CI, 1.32-1.84; prediction interval, 0.95-2.55, z = 5.19 
      [P < .0001]) for remission between the SDAM and placebo groups. A pooled effect 
      of 1.58 (95%CI, 1.37-1.83; prediction interval, 1.00-2.51, z = 6.34 [P < .0001]) 
      for adverse events and 0.72 (95%CI, 0.48-1.08; prediction interval, 0.46-1.12; z 
      = -1.58 [P = .113]) for serious adverse events was observed. No significant 
      publication bias was noticed. The quality of the evidence was rated as high. 
      Adjunct SDAM increased remission in patients and had no significant effect on 
      serious adverse events compared to placebo. Therefore, we conclude that SDAM 
      drugs can be an effective and safe antidepressant augmentation strategy in 
      patients with major depressive disorder.
CI  - (c) 2021, The American College of Clinical Pharmacology.
FAU - Mishra, Archana
AU  - Mishra A
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Sarangi, Sudhir Chandra
AU  - Sarangi SC
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Maiti, Rituparna
AU  - Maiti R
AUID- ORCID: 0000-0003-4063-9178
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, 
      India.
FAU - Sood, Mamta
AU  - Sood M
AD  - Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Reeta, K H
AU  - Reeta KH
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220208
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Antidepressive Agents)
RN  - 333DO1RDJY (Serotonin)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Antidepressive Agents/adverse effects
MH  - Depression
MH  - *Depressive Disorder, Major/drug therapy
MH  - Dopamine
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Serotonin/therapeutic use
OTO - NOTNLM
OT  - aripiprazole
OT  - augmentation strategy
OT  - brexpiprazole
OT  - major depression
OT  - meta-analysis
OT  - serotonin-dopamine activity modulators
EDAT- 2021/12/31 06:00
MHDA- 2022/04/30 06:00
CRDT- 2021/12/30 12:49
PHST- 2021/11/29 00:00 [received]
PHST- 2021/12/27 00:00 [accepted]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2021/12/30 12:49 [entrez]
AID - 10.1002/jcph.2022 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2022 Jun;62(6):721-732. doi: 10.1002/jcph.2022. Epub 2022 Feb 
      8.